       Document 0009
 DOCN  M95B0009
 TI    Yeast retrotransposon particles as antigen delivery systems.
 DT    9511
 AU    Kingsman AJ; Burns NR; Layton GT; Adams SE; British Bio-technology Ltd.,
       Oxford, United Kingdom.
 SO    Ann N Y Acad Sci. 1995 May 31;754:202-13. Unique Identifier : AIDSLINE
       MED/95351602
 AB    The development of technologies to produce recombinant proteins for use
       in the pharmaceutical industry has made substantial advances, in
       particular in the area of generating antigens containing multiple copies
       of important immunological regions. One such antigen-carrier system is
       based on the ability of a protein encoded by the yeast retrotransposon,
       Ty, to self-assemble into virus-like particles. Ty-fusion proteins
       retain this ability to form particles, and a range of hybrid VLPs
       carrying a variety of heterologous antigens have been produced and shown
       to induce potent immune responses. In particular, hybrid VLPs carrying
       the core protein p24 of HIV (p24-VLPs) have been shown to induce
       antibody and T-cell proliferative responses in both experimental animals
       and human volunteers, and immunization of rabbits with VLPs carrying the
       principal neutralizing determinant of HIV (V3-VLPs) resulted in the
       induction of neutralizing antibody responses and T-cell proliferation.
       Further studies with V3-VLPs have shown that this particulate antigen
       stimulates enhanced V3-specific lymphoproliferative responses as
       compared to whole recombinant gp120 or to V3 peptide conjugated to
       albumin. The V3-VLPs also induce potent CTL responses following
       immunization of mice in the absence of adjuvant. These responses are MHC
       class I restricted and are mediated by CD8-positive cells. These
       observations therefore demonstrate that hybrid Ty-VLPs induce both
       humoral and cellular immune responses against HIV and suggest that these
       immunogens may be important in combatting AIDS and other infections.
 DE    Animal  AIDS Vaccines/*CHEMISTRY/IMMUNOLOGY  Cytotoxicity, Immunologic
       Fungal Proteins/*IMMUNOLOGY  HIV Envelope Protein
       gp120/CHEMISTRY/IMMUNOLOGY  Lymphocyte Transformation  Mice  Mice,
       Inbred BALB C  Retrotransposons/*IMMUNOLOGY  Saccharomyces
       cerevisiae/*IMMUNOLOGY  T-Lymphocytes, Cytotoxic/IMMUNOLOGY  Vaccines,
       Synthetic/*CHEMISTRY/IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

